Aratana Therapeutics (NASDAQ:PETX) Rating Downgrade
Aratana Therapeutics (NASDAQ:PETX) was cut by professional analysts at Craig Hallum from Buy rating to Hold rating in analysts note issued to clients on Friday morning.
The firm’s rating downgrade was noticed by investors, as NASDAQ:PETX is right now trading -38.97% lower at $10.68 as of 06:11 New York time. Aratana Therapeutics’s stock is down -23.73% over the last 200 days. It has underperformed the S&P500, which has decreased -6.24% over the same time period.
According to data compiled by Thomson Reuters, Aratana Therapeutics (NASDAQ:PETX)’s stock is covered by 8 equity analysts across the Street, with 0 analysts giving it a Sell rating, 9 a Buy rating, while 0 consider it a Hold. The 12-month consensus target price for the stock is $26, which reflects an upside potential of 143.45% over the current price.
NASDAQ:PETX Price Chart & Trend
The stock price of Aratana Therapeutics has plunged 23.73% over the last 200 days, and is in strong down trend. In the last 50 and 100 days, Aratana Therapeutics is down 40.82% and down 16.44%, respectively. Our stocks momentum model is shown on the price chart below.
Mpm Asset Management Llc had the largest stake with ownership of 2.12 million shares as of Q2 2015 for 5.36% of the fund’s portfolio. Sio Capital Management Llc is another very bullish investment manager who is having 404,738 shares of Aratana Therapeutics or 3.02% of their fund’s portfolio. Further, Westend Capital Management Llc have 1.61% of their fund’s portfolio invested in the company for 90,535 shares. The New York-based fund Awm Investment Company Inc. disclosed it had purchased so far a stake worth about 1.29% of the investment manager’s stock portfolio in Aratana Therapeutics. The New York-based fund Iguana Healthcare Management Llc is also positive about the stock, possessing 600,000 shares or 0.95% of their fund’s portfolio.
Over the last six months, Aratana Therapeutics NASDAQ:PETX has seen 0 insider purchases, and 2 insider selling transactions. The net result was for 2 transactions, worth $480,816.
Aratana Therapeutics (NASDAQ:PETX) Profile
Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions, such as pain and inflammation, stimulation of appetite, cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs, or both.
Aratana Therapeutics (NASDAQ:PETX) traded down -38.97% on 25 September, hitting $10.68. A total of 2.95M shares of the company’s stock traded hands. This is up from average of 354,239 shares. Aratana Therapeutics has a 52 week low of $9.20 and a 52 week high of $20.63. The company has a market cap of $373.08M and a P/E ratio of 0.
Get the latest Aratana Therapeutics (NASDAQ:PETX) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
Aratana Therapeutics - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.